1-9 of 9
Troy H. Guthrie
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

Mazyar Shadman, Ian W. Flinn, Moshe Y. Levy, Ryan Porter, John M. Burke, Jennifer L. Cultrera, Jamal Misleh, Syed F. Zafar, Benjamin Freeman, Subramanya S. Rao, Habte Yimer, Arvind Chaudhry, Mitul D. Gandhi, Troy H. Guthrie, Edwin Kingsley, Praveen K. Tumula, Sudhir Manda, Dih-Yih Chen, Aileen Cohen, Kunthel By, Linlin Xu, Ye Liu, Jeff P. Sharman
Journal: Blood
Blood (2021) 138 (Supplement 1): 1410.
https://doi.org/10.1182/blood-2021-148544
Published: 2021
Journal Articles

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Daniel O. Persky, MD, Vasile Musteata, MD PhD, Mamia Zodelava, MD, Tetiana Perekhrestenko, MD PhD, Adolfo E Diaz, MD, Troy H. Guthrie, Jr., MD, Thomas Strack, MD, Christine Burnett, Sarah Wilson, CCRA, Tara Baetz, MD FRCPC
Journal: Blood
Blood (2019) 134 (Supplement_1): 5324.
https://doi.org/10.1182/blood-2019-128604
Published: 2019
Journal Articles

SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises

Kenneth I. Ataga, MD, Abdullah Kutlar, MD, Julie Kanter, MD, Darla Liles, MD, Rodolfo Cancado, MD, PhD, João Friedrisch, MD PhD, Troy H. Guthrie, MD, Jennifer Knight-Madden, MBBS, PhD, Ofelia A. Alvarez, MD, Victor R. Gordeuk, MD, Sandra Gualandro, MD PhD, Marina Pereira Collela, MD PhD, Wally R. Smith, MD, Scott A. Rollins, PhD, Jonathan W. Stocker, PhD, Russell P. Rother, PhD
Journal: Blood
Blood (2016) 128 (22): 1.
https://doi.org/10.1182/blood.V128.22.1.1
Published: 2016
Journal Articles

Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial

Nizar J Bahlis, MD, Alessandro Corso, Lars-Olof Mugge, Zhi-Xiang Shen, Pierre Desjardins, Anne-Marie Stoppa, MD, Olivier Decaux, Thierry De Revel, Miquel Granell, Gerald Marit, Hareth Nahi, Hilde Demuynck, Shang-Yi Huang, Supratik Basu, Troy H. Guthrie, Annette Ervin-Haynes, Nicolas Leupin, Jennifer Marek, Guang Chen, Thierry Facon
Journal: Blood
Blood (2014) 124 (21): 3458.
https://doi.org/10.1182/blood.V124.21.3458.3458
Published: 2014
Journal Articles

Reduction in Immunoglobulin (IVIG or Anti D) Use in Patients with Chronic Immune Thrombocytopenic Purpura (ITP) Receiving AMG 531: Results from Two Phase 3 Randomized Placebo-Controlled Trials.

Vinod Pullarkat, Terry B. Gernsheimer, J. Th. M. de Wolf, Troy H. Guthrie, Jr., Adrian Newland, Jeffrey S. Wasser, Solomon I. Hamburg, Sue Gao, Ron Stewart, Janet L. Nichol
Journal: Blood
Blood (2007) 110 (11): 1304.
https://doi.org/10.1182/blood.V110.11.1304.1304
Published: 2007
Journal Articles

Continued Late Conversion to Complete Remission (CR/CRu) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by Mitumprotimut-T (Id-KLH, FavId®) Active Immunotherapy.

Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas S. Lin, MD, Rene A. Castillo, MD, Nalini Janakiraman, MD, Richard G. Ghalie, MD
Journal: Blood
Blood (2007) 110 (11): 3427.
https://doi.org/10.1182/blood.V110.11.3427.3427
Published: 2007
Journal Articles

Active Immunotherapy with FavId® (Id/KLH) Following Rituximab Induction: Long-Term Follow-Up of Response Rate Improvement (RRI) and Disease Progression in Follicular Lymphoma Patients (pts).

Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas S. Lin, MD, PhD, Rene A. Castillo, MD, Nalini Janakiraman, MD, Teresa Melink, NP, Song Liu, John Bender, PharmD
Journal: Blood
Blood (2006) 108 (11): 691.
https://doi.org/10.1182/blood.V108.11.691.691
Published: 2006
Journal Articles

Rituximab Induces High Response Rate and Prolonged Remission in Chronic Idiopathic Thrombocytopenic Purpura (ITP): A Retrospective Analysis.

Salahattin M. Sanal, MD, Melissa J. Hanson, MS, Morris S. Dees, MD, Linda S. Sylvester, MD, Joseph W. Sullivan, MD, Thomas A. Marsland, MD, Shalin Shah, DO, Troy H. Guthrie, MD
Journal: Blood
Blood (2004) 104 (11): 3956.
https://doi.org/10.1182/blood.V104.11.3956.3956
Published: 2004
Journal Articles

Id/KLH Vaccine (FavId™) Following Treatment with Rituximab: An Analysis of Response Rate Improvement (RRI) and Time-to-Progression (TTP) in Follicular Lymphoma (FL).

Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas Lin, MD, Rene A. Castillo, MD, Nalini Janakiraman, MD, John F. Bender, PharmD
Journal: Blood
Blood (2004) 104 (11): 587.
https://doi.org/10.1182/blood.V104.11.587.587
Published: 2004